GlobalData Plc

The European interspinous process decompression (IPD) market, which covers 21 countries, is set to rise from $19.7 million in 2016 to around $30.3 million in 2023, representing a compound annual growth rate of 6.3%, according to GlobalData, a recognized leader in providing business information and analytics.

The company’s latest report states that key drivers of this relatively strong growth include the growing prevalence of degenerative spinal conditions due to aging populations and IPD’s advantages over traditional spinal fusion and laminectomy procedures, including motion preservation and a minimally invasive procedure with no bone removal.

Jennifer Ryan, Healthcare Analyst for GlobalData, explains: “The market for IPD devices is growing as a result of the procedure’s minimally invasive nature, capable of being performed in the outpatient setting, and the motion-preserving technology incorporated in each implant.

“However, long-term clinical data is limited for IPD devices, and device failures coupled with reports of poor effectiveness have reduced physician enthusiasm for adoption. The high price of the devices, especially compared to the gold standard spinal fusion treatment, also poses an issue. Patients in developed nations are not always reimbursed for the use of the ‘investigational’ device and patients in developing economies rely on out-of-pocket payments, limiting patient access to the technology.”

In terms of key players, the IPD devices market is fairly consolidated, composed of a mix of orthopedic and spine conglomerates as well as small players with a sole focus on spinal non-fusion devices. Medtronic and Paradigm Spine are the principal players in the IPD market, with the X-STOP and Coflex implants, respectively.

Ryan continues: “GlobalData believes drawbacks including sub-optimal long-term results for the X-STOP and the Coflex’s high cost leave the market open for others to capitalize on these concerns. The use of clinical trials focused on efficacy will be an important factor in future IPD adoption and reimbursement improvement.”

– Information based on GlobalData’s report: MediPoint: Interspinous Process Decompression Devices – Europe Analysis and Market Forecasts.

Related Intelligence

Want more Insight like this?

Our interactive subscription platform has the most comprehensive data and analysis in your industry.

Request a Demo

Related Consulting

How can we help your business?

Our consultants are skilled in every specialist market niche to deliver solutions specifically designed for your individual requirements.

Request a Callback

    Press Release Healthcare

    Majority of oncology clinical trials in China failed to meet enrolment targets

    The majority of oncology clinical trials in China that had a start date between 1 January 2012 and 31 December 2017 failed to meet the planned enrolment targets, according to GlobalData, a leading data and analytics company. The company identified and analyzed enrollment efficiencies of 324 clinical trials during the period and found that on...

    Press Release Healthcare

    Need for supportive care in oncology will increase during the next decade

    The need for effective supportive care in oncology will increase in the next decade as patients continue to live longer and cancer progresses to become more like a chronic disease. This includes the need for chemotherapy-related conditions, as chemotherapy will remain the backbone of cancer therapy for the foreseeable future, observes GlobalData, a leading data and analytics company.

    Press Release Healthcare

    World Cancer Day: What will 2018 mean for cancer research and treatment?

    The theme of this year’s World Cancer Day held on 4th February of “We can. I can.” aimed to reinforce the public message that all individuals and groups can play their part in reducing the global burden of cancer. Indeed in recent years many events have involved collaborations between traditional drug developers, cancer treatment professionals and those of varying disciplines. Examples include the IBM Watson supercomputer which is helping physicians make treatment decisions and the development of other databases such as ASCO’s CancerLinQ which assists oncologists in monitoring and analyzing patient data.

    Press Release Healthcare

    Melanoma sales are projected to rise to $5.5bn in 2026

    The value of the melanoma market was estimated to be $3.3bn across the seven major markets (7MM*) in 2016. This is expected to grow to $5.5bn in 2026, at a Compound Annual Growth Rate (CAGR) of 5.3%, according to GlobalData, a leading data and analytics company.

    Press Release Healthcare

    Global glaucoma market to reach $3.8bn by 2026

    The total glaucoma market was estimated to be $2.6bn across the seven major markets (7MM*) in 2016. This is expected to grow to $3.8bn in 2026, at a Compound Annual Growth Rate (CAGR) of 4.1%, according to GlobalData, a leading data and analytics company.

Media Enquiries

If you are a member of the press or media and require any further information, please get in touch, as we’re very happy to help.

Emailpr@globaldata.com
PhoneEMEA: +44 207 832 4399
PhoneAPAC: +91 40 6616 6809
Onlinecontact online

56% of #consumers are concerned about the impact of diet. Join us for more insight @incosmetics #cosmetics #trends… https://t.co/wJOJOqYIJF